Novo AS et al. round up €141m Symphogen financing

Novo and Danica invested €20m each, while Danica participated with its pre-financing ownership share of the additional financing.

This round is an expansion of Symphogen's previously announced €100m financing, attaining a total of €141m through a placement of preferred stock to a group of existing investors.

The fresh capital will be used to advance and expand Symphogen's proprietary oncology product pipeline of antibody mixture products.

This constitutes Danica's first independent investment in Symphogen, rather than as an LP in a venture fund. PKA first invested in Symphogen in 2011.

Based in Copenhagen, Symphogen is a biopharmaceutical company developing recombinant antibody mixtures. To date, Symphogen has raised €249m in equity from international investors including Novo, Essex Woodlands Health Ventures and PKA. The company has 90 employees.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Nordics
• Expansion
• Healthcare
• Denmark